Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
University of Washington
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
M.D. Anderson Cancer Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
Yale University
National Cancer Institute (NCI)
Mayo Clinic
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Genmab
AstraZeneca
St. Jude Children's Research Hospital
First Affiliated Hospital of Zhejiang University
National Institutes of Health Clinical Center (CC)
Genmab
Stanford University
University of Washington
Alliance for Clinical Trials in Oncology
Masonic Cancer Center, University of Minnesota
Hackensack Meridian Health
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
University Hospital, Caen
AvenCell Therapeutics, Inc.
Children's Oncology Group
Children's Oncology Group
St. Jude Children's Research Hospital
Medical University of South Carolina
CERo Therapeutics Holdings, Inc.
St. Jude Children's Research Hospital
City of Hope Medical Center
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Fate Therapeutics
Children's Cancer Group, China
Center for International Blood and Marrow Transplant Research
M.D. Anderson Cancer Center
City of Hope Medical Center
Merck Sharp & Dohme LLC
Chinese PLA General Hospital